Rituximab Reduced Disease Activity in MS Patients

2 trials show drug may be effective new therapy

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

FRIDAY, May 4, 2007 (HealthDay News) -- The drug rituximab reduces disease activity in people with the relapsing-remitting form of multiple sclerosis (MS), according to two new studies.

Rituximab selectively targets and depletes a subset of immune cells called B-cells by targeting a specific protein on the cell surface. It's the first drug designed to target B-cells and may offer a new treatment for relapsing-remitting MS.

In one study, University of California, San Francisco, researchers gave two infusions of rituximab, delivered two weeks apart, to 69 patients, while 35 other patients received a placebo.

During the following six months, the patients who received rituximab had 90 percent fewer brain lesions and 58 percent fewer drug relapses than the patients who received the placebo (14.5 percent vs. 34.3 percent).

In the second study, researchers at McGill University in Montreal gave 26 patients two infusions of rituximab two weeks apart (one course of treatment) and then gave them another course of treatment six months later. The patients were followed for at least a year.

The patients showed a 90 percent reduction in brain lesions, and the relapse rate went from an average of at least one per patient per year to only a few for the entire group of patients during the year of treatment.

Both studies were supported by Genentech Inc., and Biogen Idec., the companies marketing the drug in the United States, where it is currently approved for treating certain types of lymphoma and for a moderate to severe form of rheumatoid arthritis. Rituximab is not approved for treatment of MS.

"While these are early stage clinical trials, these results are exciting, because the current drugs available for MS are only partially effective in reducing disease activity and preventing exacerbations," Dr. Stephen Hauser, author of the California study, said in a prepared statement.

"New and more effective treatments for MS are sorely needed, especially for people who do not adequately respond to current available medications. These data are also important, because they demonstrate that B-cells, which are the precursors of antibody-producing cells, play an essential role in mediating relapses of MS," Hauser said.

The studies were expected to be presented this week at the American Academy of Neurology's annual meeting, in Boston.

More information

The American Medical Association has more about MS.

SOURCE: American Academy of Neurology, news release, May 1, 2007

--

Last Updated: